NTRK1 and glioma: We demonstrate that four multi-targeted receptor tyrosine kinase inhibitors (RTKi) and a specific inhibitor targeting the platelet-derived growth factor receptor (PDGFRi) exhibit higher toxicity in ATRX-deficient high-grade glioma cells.